CMV Vaccines: Reinfection and Antigenic Variation (Vision and auditory screening in infants born to women enrolled in ZIP)
CMV 疫苗:再感染和抗原变异(参加 ZIP 的妇女所生婴儿的视力和听觉筛查)
基本信息
- 批准号:9472616
- 负责人:
- 金额:$ 3.27万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-05-01 至 2018-04-30
- 项目状态:已结题
- 来源:
- 关键词:AdultAntibodiesAntibody ResponseAntigenic VariationAuditoryCharacteristicsChildChild health careComplexControlled StudyCytomegalovirusCytomegalovirus InfectionsCytomegalovirus VaccinesDevelopmentDiseaseEnrollmentExhibitsExposure toFemale of child bearing ageFetusGenotypeGoalsHerd ImmunityHumanHuman CharacteristicsImmuneImmune responseImmunityImmunologicsIncidenceIndividualInfantInfectionInfection preventionInterventionLeadLive BirthMinorMorbidity - disease rateMothersNatural HistoryNeurodevelopmental DisorderNeurologicNorthern EuropePopulationPregnancyPreventive InterventionPreventive vaccineRecurrenceRiskRoleSecondary toSeroprevalencesSourceTestingTherapeutic InterventionTransplant RecipientsUrban PopulationVaccinesViralViral AntibodiesVirusVirus DiseasesVisionWomanbaseburden of illnesscongenital infectiondesignfetal infectiongenome-widehearing impairmentin uterooffspringprophylacticscreeningtherapeutic vaccinetransmission processviral transmissionvirology
项目摘要
DESCRIPTION (provided by applicant): Human cytomegalovirus (HCMV) infection represents the most common viral infection transmitted in-utero and is a significant cause of neurodevelopmental disorders in children. The rate of congenital HCMV infection ranges from 0.2-1.0% of live births in the US and exceeds 1% in many parts of the world. Although maternal infection during pregnancy (primary maternal infection) represents a significant risk for virus transmission to the fetus and disease, infection and transmission to the fetus in women with existing immunity to this virus (non-primary maternal infection) is frequent. Disease in babies infected following non-primary maternal infection is well documented. Worldwide, including most US populations, the disease burden in infected infants born to women with non-primary infections exceeds that of offspring of women with primary maternal infection. In this proposal we will explore two mechanisms of non-primary maternal infections, reinfection with new strain of viruses and recurrence/reactivation of a persistent infection. Our goals are to define virological characteristics of non-primary infections and parameters of HCMV specific immunity in a highly seroimmune population in which non-primary maternal infections account for the vast majority of infected babies. We will also determine the incidence of the most common long term sequelae of congenital HCMV infection, hearing loss, in infected babies. We anticipate these studies will help identify host responses associated with intrauterine transmission and damaging fetal infections in this population of women with non-primary infection and could aid in the rationale development of effective prophylactic and possibly therapeutic vaccines to limit the morbidity from this congenital infection.
描述(由申请人提供):人巨细胞病毒(HCMV)感染是最常见的宫内传播病毒感染,是儿童神经发育障碍的重要原因。先天性HCMV感染率在美国占活产婴儿的0.2-1.0%,在世界许多地区超过1%。虽然怀孕期间的孕产妇感染(原发性孕产妇感染)是病毒传播给胎儿和疾病的重大风险,但对这种病毒具有免疫力的妇女(非原发性孕产妇感染)感染和传播给胎儿的情况很常见。非原发母亲感染后感染婴儿的疾病有充分的记录。在世界范围内,包括大多数美国人口,非原发感染妇女所生的受感染婴儿的疾病负担超过了原发母亲感染妇女的后代的疾病负担。在这个建议中,我们将探讨两种非原发母体感染的机制,新病毒株的再感染和持续感染的复发/再激活。我们的目标是确定非原发性感染的病毒学特征和高度血清免疫人群的HCMV特异性免疫参数,其中非原发性母体感染占绝大多数感染婴儿。我们还将确定最常见的先天性HCMV感染的长期后遗症,听力损失,在感染婴儿的发生率。我们预计这些研究将有助于确定与子宫内传播和非原发性感染妇女群体中破坏性胎儿感染相关的宿主反应,并有助于开发有效的预防性和可能的治疗性疫苗,以限制这种先天性感染的发病率。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
William Jarvis Britt其他文献
William Jarvis Britt的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('William Jarvis Britt', 18)}}的其他基金
Tegument Envelope Protein Interactions in CMV Envelopment
CMV 包膜中的皮膜包膜蛋白相互作用
- 批准号:
10573700 - 财政年份:2022
- 资助金额:
$ 3.27万 - 项目类别:
CMV Vaccines: Reinfection and Antigenic Variation
CMV 疫苗:再感染和抗原变异
- 批准号:
10019411 - 财政年份:2019
- 资助金额:
$ 3.27万 - 项目类别:
CMV Vaccines: Reinfection and Antigenic Variation
CMV 疫苗:再感染和抗原变异
- 批准号:
10488568 - 财政年份:2019
- 资助金额:
$ 3.27万 - 项目类别:
CMV Vaccines: Reinfection and Antigenic Variation
CMV 疫苗:再感染和抗原变异
- 批准号:
10686167 - 财政年份:2019
- 资助金额:
$ 3.27万 - 项目类别:
Inflammation and Hearing Loss Following Congenital CMV Infection
先天性巨细胞病毒感染后的炎症和听力损失
- 批准号:
9759910 - 财政年份:2017
- 资助金额:
$ 3.27万 - 项目类别:
Inflammation and Hearing Loss Following Congenital CMV Infection
先天性巨细胞病毒感染后的炎症和听力损失
- 批准号:
10238050 - 财政年份:2017
- 资助金额:
$ 3.27万 - 项目类别:
HCMV miRNA Regulation of Secretion and Formation of the Viral Assembly Compartment
HCMV miRNA 对病毒装配室的分泌和形成的调节
- 批准号:
9883699 - 财政年份:2016
- 资助金额:
$ 3.27万 - 项目类别:
HCMV miRNA Regulation of Secretion and Formation of the Viral Assembly Compartment
HCMV miRNA 对病毒装配室的分泌和形成的调节
- 批准号:
9250666 - 财政年份:2016
- 资助金额:
$ 3.27万 - 项目类别:
Congenital CMV and CNS Infection Mechanisms of Protective Immunity
先天性巨细胞病毒和中枢神经系统感染的保护性免疫机制
- 批准号:
8450754 - 财政年份:2011
- 资助金额:
$ 3.27万 - 项目类别:
Congenital CMV and CNS Infection Mechanisms of Protective Immunity
先天性巨细胞病毒和中枢神经系统感染的保护性免疫机制
- 批准号:
8263366 - 财政年份:2011
- 资助金额:
$ 3.27万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 3.27万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 3.27万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 3.27万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 3.27万 - 项目类别:
Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 3.27万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 3.27万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 3.27万 - 项目类别:
Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
- 批准号:
10699504 - 财政年份:2023
- 资助金额:
$ 3.27万 - 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
- 批准号:
10491642 - 财政年份:2023
- 资助金额:
$ 3.27万 - 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
- 批准号:
10782567 - 财政年份:2023
- 资助金额:
$ 3.27万 - 项目类别:














{{item.name}}会员




